Skip to main content

Table 2 Demographic and clinical features of total cohort and AIT subgroups in patients who completed or withdrew from the AIT program

From: Impact on quality of life and safety of sublingual and subcutaneous immunotherapy in children with severe house dust mite and pollen-associated allergic rhinoconjunctivitis

 Total cohortPollen SCITPollen SLITHDM SLIT
CompletedWithdrewP-valueCompletedWithdrewP-valueCompletedWithdrewP-valueCompletedWithdrewP-value
Frequency118 (71%)49 (29%) 70 (82%)15 (18%) 13 (62%)8 (38%) 35 (49%)26 (51%) 
Age (years)
Median (IQR)
12 (10–14)14 (12–16)< 0.00113 (11–14)15 (14–16)< 0.00111 (10–15)12 (9–16)0.510 (9–13)14 (11–16)0.003
Gender
 Male86 (73%)29 (59%)0.0855 (79%)9 (60%)0.29 (69%)6 (75%)1.0a22 (63%)14 (54%)0.5
 Female32 (27%)20 (41%)15 (21%)6 (40%)4 (31%)2 (25%)13 (37%)12 (46%)
Race
 White European87 (74%)31 (26%)0.157 (81%)12 (80%)0.6a13 (100%)7 (88%)0.4a17 (49%)11 (42%)0.6
 Other30 (61%)49 (39%)13 (19%)3 (20%)0 (0%)1 (12%)18 (51%)15 (58%)
AR symptoms
 Eyes8 (7%)3 (6%)1.0a3 (4%)1 (7%)0.8a3 (23%)1 (12%)1.02 (6%)1 (4%)0.9a
 Nose11 (9%)4 (8%)4 (6%)0 (0%)1 (8%)1 (12%)6 (17%)3 (11%)
 Eyes + nose99 (84%)42 (86%)63 (90%)14 (93%)9 (69%)6 (75%)27 (77%)22 (85%)
Medication
 OA only3 (3%)01.0a1 (1%)0%0.3a0 (0%)0 (0%)0.4a2 (6%)0 (0%)0.6a
 OA + Adjuncts107 (90%)47 (88%)65 (93%)12 (80%)13 (100%)7 (88%)29 (83%)24 (92%)
 Systemics8 (7%)6 (12%)4 (6%)3 (20%)0 (0%)1 (12%)4 (11%)2 (8%)
Other atopic disease
 Asthma55 (47%)17 (35%)0.235 (50%)6 (40%)0.26 (46%)2 (25%)1.0a14 (40%)9 (35%)1.0a
 AD11 (9%)3 (6%)7 (10%)1 (7%)0 (0%)0 (0%)4 (11%)2 (8%)
 Asthma + AD29 (25%)17 (35%)12 (17%)6 (40%)2 (15%)1 (12%)15 (43%)10 (38%)118
Mono-sensitised to AIT
 Yes57 (48%)14 (29%)0.0243 (61%)4 (27%)0.036 (46%)3 (38%)1a8 (23%)7 (27%)0.7
 No61 (52%)35 (71%)27 (39%)11 (73%)7 (54%)5 (62%)27 (77%)19 (73%)
Median baseline RQLQ (IQR)65 (36–89)59 (38–85)0.577 (38–97)75 (41–89)0.556 (45–115)80 (80–80)0.951 (33–79)15 (43%)0.3
Median baseline VAS (IQR)7 (5–8)6 (4–8)0.87 (4–8)7 (4–9)0.98 (6–9)7 (6–7)0.47 (5–7)6 (2–7)0.9
  1. AIT allergy immunotherapy, AR allergic rhinoconjunctivitis, HDM house dust mite, IQR interquartile range, OA oral antihistamines, RQLQ rhinoconjunctivitis quality of life questionnaire, SCIT subcutaneous immunotherapy, SLIT sublingual immunotherapy, VAS visual analogue score
  2. P-values between completed and discontinued subgroups using Chi squared Test for nominal and Mann–Whitney U Test for continuous variables. aFisher’s Exact test used as data violates conditions for Chi squared Test